Carcinogen Alphabet: “Z” for Zidovudine

Zidovudine also known as azidothymidine, is a antiretroviral medication which is either used on its own of as part of a combination of antiretroviral drugs given to a patient to treat and prevent transmission of HIV.

The IARC has evaluated zidovudine and although there is no current evidence of carcinogenicity in humans there is sufficient evidence in animal studies of its carcinogenicity. As such the IARC classifies it as possibly carcinogenic to humans (Group 2B).

In support of the “No Time to Lose” Campaign the SEL Group will be running an “Alphabet of Carcinogens” campaign and each week we shall release details regarding a different well known carcinogen.

For reference or further information on Zidovudine visit:

Newsletter

Sign up to our newsletter and be kept up to date with announcements, news and offers.
* denotes a required field.

Get in touch


34 Milford Road
Stafford
Staffordshire
ST17 0JU


+44 (0)1785 662967
+44 (0)7801 710159


info@selgroup.co.uk

Say Hello.

Share This